We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina (ILMN) Stock Moves -1.75%: What You Should Know
Read MoreHide Full Article
Illumina (ILMN - Free Report) closed the most recent trading day at $237.76, moving -1.75% from the previous trading session. This move was narrower than the S&P 500's daily loss of 2.93%. Elsewhere, the Dow lost 3.04%, while the tech-heavy Nasdaq lost 0.27%.
Heading into today, shares of the genetic testing tools company had lost 19.46% over the past month, outpacing the Medical sector's loss of 24.66% and the S&P 500's loss of 31.71% in that time.
ILMN will be looking to display strength as it nears its next earnings release. In that report, analysts expect ILMN to post earnings of $1.24 per share. This would mark a year-over-year decline of 22.5%. Meanwhile, our latest consensus estimate is calling for revenue of $854.06 million, up 0.95% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.85 per share and revenue of $3.89 billion. These totals would mark changes of +4.26% and +9.74%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for ILMN. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.16% lower. ILMN currently has a Zacks Rank of #3 (Hold).
Digging into valuation, ILMN currently has a Forward P/E ratio of 35.34. This valuation marks a premium compared to its industry's average Forward P/E of 24.36.
Also, we should mention that ILMN has a PEG ratio of 1.77. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.42 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 62, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Illumina (ILMN) Stock Moves -1.75%: What You Should Know
Illumina (ILMN - Free Report) closed the most recent trading day at $237.76, moving -1.75% from the previous trading session. This move was narrower than the S&P 500's daily loss of 2.93%. Elsewhere, the Dow lost 3.04%, while the tech-heavy Nasdaq lost 0.27%.
Heading into today, shares of the genetic testing tools company had lost 19.46% over the past month, outpacing the Medical sector's loss of 24.66% and the S&P 500's loss of 31.71% in that time.
ILMN will be looking to display strength as it nears its next earnings release. In that report, analysts expect ILMN to post earnings of $1.24 per share. This would mark a year-over-year decline of 22.5%. Meanwhile, our latest consensus estimate is calling for revenue of $854.06 million, up 0.95% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.85 per share and revenue of $3.89 billion. These totals would mark changes of +4.26% and +9.74%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for ILMN. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.16% lower. ILMN currently has a Zacks Rank of #3 (Hold).
Digging into valuation, ILMN currently has a Forward P/E ratio of 35.34. This valuation marks a premium compared to its industry's average Forward P/E of 24.36.
Also, we should mention that ILMN has a PEG ratio of 1.77. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.42 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 62, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.